The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform

Chang Tong - One of the best experts on this subject based on the ideXlab platform.

  • ultrasonographic prediction of Esophagus Varices hemorrhage caused by cirrhosis of liver
    Modern Medicine Health, 2010
    Co-Authors: Chang Tong
    Abstract:

    To predict Esophagus Varices hemorrhage caused by liver cirrhosis in 186 hepatitis patients.Methods:The diameter of liver portal vein and the diameter of splenic vein were measured by B mode ultrasound.Results:The diameter of liver portal vein and the diameter of splenic vein was(1.68±0.23)cm and(1.24±0.18)cm respectively,which was larger than(1.32±0.21)cm and(1.02±0.22)cm of non-bleeding group cirrhosis of liver with significant difference between the two groups(P0.05).There was the remarkable positive correlation between the diameter of liver portal vein and splenic vein and Esophagus Varices hemorrhage rate caused by cirrhosis of liver(P 0.001).The diameter of liver portal vein≥1.6 cm and the diameter of splenic vein≥1.1 cm could be the reference indexes predicting the danger of hemorrhage.Conclusion:Determining portal vein of liver and splenic veinby B mode ultrasonography is considered as a safe and efficient way in predicting dangerous Esophagus Varices hemorrhage.

  • application of b mode ultrasound in the prediction of Esophagus Varices hemorrhage caused by hepatocirrhosis
    Modern Medicine Health, 2006
    Co-Authors: Chang Tong
    Abstract:

    Objective:To study the application of B-mode ultrasound in the prediction of Esophagus Varices hemorrhage caused by hepatocirrhosis.Methods:The diameter of liver portal vein and splenic vein were respectively measured by B-mode ultrasound.Results:The diameter of liver portal vein and splenic vein was (1.68±0.23)cm and (1.34±0.18)cm respectively in the cirrhosis bleeding group,and significanty larger than (1.32±0.21)cm in the cirrhosis non-bleeding group(all P0.05).Both the diameter of liver portal vein and the diameter of splenic vein were positively correlated with the rate of Esophagus Varices hemorrhage caused by hepatocirrhosis (P0.01).The diameter of liver portal vein≥1.6 cm and the diameter of splenic vein≥1.1 cm could be the reference indices for predicting the danger of hemorrhage.Conclusion:B-mode ultrasound for determining the portal vein of liver and splenic vein can be considered as a safe and effective way in the prediction of dangerous Esophagus verices hemorrhage.

A I Jingang - One of the best experts on this subject based on the ideXlab platform.

  • Varices of fundus of stomach and Esophagus treated by the endoscopic variceal ligation combining with the injection of histoacryl
    Guide of China Medicine, 2009
    Co-Authors: A I Jingang
    Abstract:

    Objective Result into the clinical efficacy of the rup tured hemorrhage of Varices of fundus of stomach and Esophagus (RHVFSE) treated by the endoscopic variceal ligaton ( EVL) combining with the injection of histoacryl. Method The retrospective analysis was made on the clinical materials concerning 92 cases of RHVFSE patients treated by the continuous EVL and 16 cases of patients who had ruptured hemorrhage of Varices of fundus of stomach and was more serious after the EVL. Result For 92 EVL cases, it was 2.3 times each case and 772 ligations for 174 case / times, 64 cases produced effect (69.5%) , 24 cases were effective (26.2%) and 4 cases were failed due to the complication of massive hemorrhage with the effective rate being 95.7%.Among them, there were 16 cases had Ⅳ~ⅤGrade Varices of fundus of stomach after 4~12 weeks of EVL with the incidence being 17.4%.The Varices of fundus of stomach disappeared after injecting the histoacryl and the histoacryl was drained out after 5 months without hemorrhage any more. Conclusion The effi cacy of ruptured hemorrhage of Esophagus Varices treated by EVL is obvious and for the ruptured hemorrhage of Varices of fundus of stomach induced by EVL, the effi cacy will be satisfactory if combining with the injection of histoacryl.

Hu Bin - One of the best experts on this subject based on the ideXlab platform.

  • clinical analysis on ruptured hemorrhage of Varices of fundus of stomach and Esophagus treated by the endoscopic variceal ligation combining with the injection of histoacryl
    Hebei Medicine, 2006
    Co-Authors: Hu Bin
    Abstract:

    Objective: To probe into the clinical efficacy of the ruptured hemorrhage of Varices of fundus of stomach and Esophagus(RHVFSE) treated by the endoscopic variceal ligaton(EVL) combining with the injection of histoacryl.Method: The retrospective analysis was made on the clinical materials concerning 46 cases of RHVFSE patients treated by the continuous EVL and 8 cases of patients who had ruptured hemorrhage of Varices of fundus of stomach and was more serious after the EVL.Result: For 46 EVL cases,it was 2.1 times each case and 386 ligations for 87 case/times,32 cases produced effect(69.5%),12 cases were effective(26.2%) and 2 cases were failed due to the complication of massive hemorrhage with the effective rate being 95.7%.Among them,there were 8 cases had IV-V Grade Varices of fundus of stomach after 4～12 weeks of EVL with the incidence being 17.4%.The Varices of fundus of stomach disappeared after injecting the histoacryl and the histoacryl was drained out after 6 months without haemorrage any more.Conclusion: The efficacy of ruptured hemorrhage of Esophagus Varices treated by EVL is obvious and for the ruptured hemorrhage of Varices of fundus of stomach induced by EVL,the efficacy will be satisfactory if combining with the injection of histoacryl.

Luan Shuangmei - One of the best experts on this subject based on the ideXlab platform.

  • effect of endoscopic esophageal varical ligation combined with pantical splenic embolization for Esophagus Varices
    China Journal of Endoscopy, 2005
    Co-Authors: Luan Shuangmei
    Abstract:

    To evaluate the feasibility and eflicacy of a method of endoscopic esophageal variceal ligation(EVL) combined with partial splenic embolization (PSE) for the patients with portal hypertension. Thirty-five patients with portal hypertension under went EVL-PSE accomparied with esophageal variceal bleading and hypersplenism. The patient′s Esophageal variceals were complete embolized. During 3~36 months follow up, recurrent bleeding was 8.6%,postoperactive the splent volumes were less, around blood white cell and platelet count were significantly increase (P0.001), splenic vein, postoperative portal trunk were less and its flow volume and velocity were significantly reduced. [Conclusions] EVL-PSE can be carried out sufely in the clinical treatment for patients with portal hypertension. It can be quick embolized and less injured than surgery.

Kavakli Kaan - One of the best experts on this subject based on the ideXlab platform.

  • Single-center experience: Use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder
    'Informa UK Limited', 2008
    Co-Authors: Yilmaz Deniz, Karapinar Buelent, Balkan Can, Akisue Mete, Kavakli Kaan
    Abstract:

    WOS: 000255989700005PubMed ID: 18484474Coagulopathy is an important cause of mortality in critically ill children. Traditional therapies to correct coagulopathy lead to great time delays and cause fluid overload in patients. The authors report the effectiveness and safety of the activated recombinant factor VII (rFVIIa) administration in a series of 13 nonhemophiliac children with acute, life-threatening bleeding. In this retrospective study, the records of the patients who were not diagnosed with congenital hemorrhagic disorder and were administered rFVIIa due to any other reason in Ege University Faculty of Medicine, Department of Pediatrics, between February 2002 and February 2007 were reviewed retrospectively. Thirteen nonhemophiliac patients with acute life-threatening bleeding and ages ranging from 2 days to 15 years received rFVIIa over a 5-year period. Three patients were diagnosed with hemaphagocytic lymphohistiocytosis, 4 with prematurity, sepsis, and disseminated intravascular coagulation (DIC), 5 with sepsis, multiple organ dysfunction syndrome, and DIC, and 1 with acute liver failure. Severe bleeding resulted from pulmonary (n=3), lower gastrointestinal system (n=2), Esophagus Varices (n=1), pulmonary and gastrointestinal system (n=4), pulmonary, gastrointestinal system, and intracranial hemorrhage (n=1), and gastrointestinal system and intracranial hemorrhage (n = 2). Median frequency of rFVIIa administration was 3 per patient (range 2{15) and median dose of rFVIIa was 90 g/kg, ranging from 60 to 135 g/kg each administration. All of the patients were given fresh frozen plasma and if necessary platelet transfusion (n = 10) or fibrinogen concentrate (n = 3) before administration of rFVIIa. In 6 patients, lack of success to control bleeding by conventional methods was the only cause to start rFVIIa. In 7 patients, the need for volume restriction was also a significant contributing factor in deciding to start rFVIIa. Median PT was 32.9 s (range: 19{65) before rFVIIa administration and it was decreased to 11.6 s (range: 10.7{12.8), 2{3 h after rFVIIa infusion. Bleeding was stopped completely in 10 patients at least for 24 h and decreased in 3 patients 30{45 min after rFVIIa administration. Two patients had thrombotic complications attributed to rFVIIa administration. No other complication was observed in the other patients. In this retrospective study, rFVIIa was found to be effective at controlling severe hemorrhagic symptoms of different etiologies in children without congenital hemorrhagic disorder. In addition to the rapid control of bleeding, administration of this agent improved fluid balance and led to a reduction in blood product requirements in critically ill children. However, survival was still poor (23%), and 2/13 (15.4%) patients developed venous and arterial thrombosis within 3 h of treatment. The authors emphasize that in acquired, acute life-threatening bleeding, simultaneous administration of rFVIIa with conventional treatment may contribute to patient survival. However, the risk of thromboembolism should be considered before this treatment is given